Compositions and methods for treating gjb2-related hearing loss

HK40137517APending Publication Date: 2026-09-11DECIBEL THERAPEUTICS INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026127030
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2026-08-04
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The disclosure provides polynucleotides and nucleic acid vectors containing a gap junction protein beta 2 (GJB2) regulatory construct operably linked to a polynucleotide encoding a Gjb2 protein (e.g., a wild-type human Gjb2 protein). These polynucleotides and vectors can be used to express Gjb2 in GJB2-expressing cells, including cochlear supporting cells, and can, thus, be used for the treatment of subjects having or at risk of developing GJB2-related hearing loss.
Need to check novelty before this filing date? Find Prior Art

Description

This disclosure provides polynucleotide and nucleic acid vectors containing a GJB2 regulatory construct operatively linked to a polynucleotide encoding a gap junction protein β2 (Gjb2) protein (e.g., wild-type human Gjb2 protein). These polynucleotides and vectors can be used to express Gjb2 in cells expressing GJB2, and therefore can be used to treat subjects with or at risk of developing GJB2-related hearing loss, including cochlear support cells. Abstract

Claims

Claims1 . A nucleic acid vector comprising, in 5’-to-3’ order:(a) a GJB2 regulatory construct having a sequence selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 2, and a sequence having at least 90% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, operably linked to:(b) a human GJB2 coding sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 28, a sequence having at least 90% sequence identity to SEQ ID NO: 3 and comprising at least 50% fewer CG dinucleotides than wild-type GJB2, and a sequence having at least 90% sequence identity to SEQ ID NO: 4 or SEQ ID NO: 28, operably linked to:(c) a polyadenylation (polyA) signal sequence.

2. The nucleic acid vector of claim 1 , wherein the GJB2 regulatory construct has the sequence of SEQ ID NO: 1 and the human GJB2 coding sequence has the sequence of SEQ ID NO: 3.

3. The nucleic acid vector of claim 1 , wherein the GJB2 regulatory construct has the sequence of SEQ ID NO: 1 and the human GJB2 coding sequence has the sequence of SEQ ID NO: 4.

4. The nucleic acid vector of claim 1 , wherein the GJB2 regulatory construct has the sequence of SEQ ID NO: 1 and the human GJB2 coding sequence has the sequence of SEQ ID NO: 28.

5. The nucleic acid vector of claim 1 , wherein the GJB2 regulatory construct has the sequence of SEQ ID NO: 2; and the human GJB2 coding sequence has the sequence of SEQ ID NO: 3.

6. The nucleic acid vector of claim 1 , wherein the GJB2 regulatory construct has the sequence of SEQ ID NO: 2; and the human GJB2 coding sequence has the sequence of SEQ ID NO: 4.

7. The nucleic acid vector of claim 1 , wherein the GJB2 regulatory construct has the sequence of SEQ ID NO: 2; and the human GJB2 coding sequence has the sequence of SEQ ID NO: 28.

8. The nucleic acid vector of any one of claims 1 -7, wherein the polyA signal sequence has at least 90% sequence identity to SEQ ID NO: 6 or SEQ ID NO: 7.

9. The nucleic acid vector of claim 8, wherein the polyA signal sequence has the sequence of SEQ ID NO: 6.

10. The nucleic acid vector of claim 8, wherein the polyA signal sequence has the sequence of SEQ ID NO: 7.11 . The nucleic acid vector of any one of claims 1 -10, wherein the vector comprises a stop codon positioned at the 3’ end of the GJB2 coding sequence.

12. The nucleic acid vector of any one of claims 1 -11 , wherein the vector further comprises a first polynucleotide having at least 90% sequence identity to SEQ ID NO: 8 that comprises a first member of an ITR pair and is positioned 5’ of the GJB2 regulatory construct sequence and a second polynucleotide having at least 90% sequence identity to SEQ ID NO: 9 that comprises a second member of an ITR pair and is positioned 3’ of the polyA signal sequence.

13. The nucleic acid vector of any one of claims 1 -11 , wherein the vector further comprises a first polynucleotide having at least 90% sequence identity to SEQ ID NO: 10 that comprises a first member of an ITR pair and is positioned 5’ of the GJB2 regulatory construct sequence and a second polynucleotide having at least 90% sequence identity to SEQ ID NO: 11 that comprises a second member of an ITR pair and is positioned 3’ of the polyA signal sequence.

14. The nucleic acid vector of any one of claims 1 -13, wherein the nucleic acid vector is a viral vector.

15. The nucleic acid vector of claim 14, wherein the viral vector is an adeno-associated virus (AAV) vector.

16. A composition comprising the nucleic acid vector of any one of claims 1 -15; and a pharmaceutically acceptable carrier, diluent, or excipient.

17. A method of treating a subject having or at risk of developing GJB2-related hearing loss, comprising administering to an inner ear of the subject a therapeutically effective amount of the nucleic acid vector of any one of claims 1 -15 or the composition of claim 16.

18. The method of claim 17, wherein the GJB2-related hearing loss is DFNB1 or DFNA3.

19. The method of claim 18, wherein the subject has a mutation in GJB2, a mutation in GJB6, or a mutation in both GJB2 and GJB6.